GlassScriptPhysician profile
Theodore C Osuala
NPI 1356428833
$6,327.18
in general payments reported to CMS, 2019-2025
24 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $435 · 2021: $858 · 2022: $522 · 2023: $837 · 2024: $1,185 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.65 |
| Education | $103.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,135.43 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $843.78 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $773.62 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $562.65 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $531.62 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $520.47 | 2020-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $385.89 | 2021-2025 | Invega Sustenna |
| Allergan, INC. | $327.02 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $302.87 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $204.59 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $189.43 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $101.71 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $86.45 | 2023-2025 | Qelbree, Qelbree |
| Indivior INC. | $76.86 | 2022-2024 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $70.11 | 2023-2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $41.74 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $33.46 | 2021 | |
| Eisai INC. | $33.25 | 2021 | |
| Tris Pharma INC | $21.20 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $20.61 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.09 | 2023 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $16.87 | 2025 | Invega Sustenna |
| Orexo US, INC. | $14.46 | 2025 | Zubsolv |
| Jazz Pharmaceuticals INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Osuala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.